cbdMD, Inc. Common Stock (YCBD) is a publicly traded Healthcare sector company. As of July 7, 2026, YCBD trades at $0.73 with a market cap of $7.19M and a P/E ratio of 5.02. YCBD moved +3.23% today. Year to date, YCBD is -47.65%; over the trailing twelve months it is -17.21%. Its 52-week range spans $0.47 to $6.54. Analyst consensus is buy with an average price target of $2.00. Rallies surfaces YCBD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
cbdMD Secures GRAS Status for 200 mg Daily Broad Spectrum CBD: cbdMD completed a self-affirmed GRAS determination supporting safe consumption of up to 200 mg per day of its broad spectrum CBD for healthy adults. The conclusion, based on peer-reviewed studies in rodents, human volunteers and canines, distinguishes cbdMD’s safety profile and could drive product adoption in wellness and healthcare channels.
| Metric | Value |
|---|---|
| Price | $0.73 |
| Market Cap | $7.19M |
| P/E Ratio | 5.02 |
| EPS | $0.14 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.54 |
| 52-Week Low | $0.47 |
| Volume | 214.53K |
| Avg Volume | 0 |
| Revenue (TTM) | $19.98M |
| Net Income | $-2.66M |
| Gross Margin | 59.38% |
1 analysts cover YCBD: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.00.